LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 10 of 15: Cell count and normalized growth rate inhibition values within biological replicate 3. - Dataset (ID:20247)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Barasertib | 3.33 | uM | LJP5 | 3 | D08 | 72 | hr | 1401 | 1334 | 4545 | 0.2935 | -0.0287 |
| SK-BR-3 | Barasertib | 10 | uM | LJP5 | 1 | D07 | 72 | hr | 1401 | 1402 | 3978 | 0.3524 | 0.0002 |
| SK-BR-3 | Barasertib | 10 | uM | LJP5 | 2 | D07 | 72 | hr | 1401 | 1466 | 4213 | 0.3480 | 0.0287 |
| SK-BR-3 | Barasertib | 10 | uM | LJP5 | 3 | D07 | 72 | hr | 1401 | 1412 | 4545 | 0.3106 | 0.0044 |
| SK-BR-3 | Vemurafenib | 0.04 | uM | LJP5 | 1 | C18 | 72 | hr | 1401 | 4308 | 3978 | 1.0828 | 1.1085 |
| SK-BR-3 | Vemurafenib | 0.04 | uM | LJP5 | 2 | C18 | 72 | hr | 1401 | 4659 | 4213 | 1.1058 | 1.1307 |
| SK-BR-3 | Vemurafenib | 0.04 | uM | LJP5 | 3 | C18 | 72 | hr | 1401 | 4694 | 4545 | 1.0326 | 1.0381 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 1 | C17 | 72 | hr | 1401 | 4107 | 3978 | 1.0323 | 1.0427 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 2 | C17 | 72 | hr | 1401 | 4621 | 4213 | 1.0968 | 1.1198 |
| SK-BR-3 | Vemurafenib | 0.12 | uM | LJP5 | 3 | C17 | 72 | hr | 1401 | 4296 | 4545 | 0.9450 | 0.9345 |
| SK-BR-3 | Vemurafenib | 0.37 | uM | LJP5 | 1 | C16 | 72 | hr | 1401 | 4219 | 3978 | 1.0604 | 1.0795 |
| SK-BR-3 | Vemurafenib | 0.37 | uM | LJP5 | 2 | C16 | 72 | hr | 1401 | 3768 | 4213 | 0.8943 | 0.8642 |
| SK-BR-3 | Vemurafenib | 0.37 | uM | LJP5 | 3 | C16 | 72 | hr | 1401 | 4540 | 4545 | 0.9987 | 0.9985 |
| SK-BR-3 | Vemurafenib | 1.11 | uM | LJP5 | 1 | C15 | 72 | hr | 1401 | 4009 | 3978 | 1.0076 | 1.0101 |
| SK-BR-3 | Vemurafenib | 1.11 | uM | LJP5 | 2 | C15 | 72 | hr | 1401 | 4346 | 4213 | 1.0315 | 1.0394 |
| SK-BR-3 | Vemurafenib | 1.11 | uM | LJP5 | 3 | C15 | 72 | hr | 1401 | 4038 | 4545 | 0.8883 | 0.8652 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 1 | C14 | 72 | hr | 1401 | 4046 | 3978 | 1.0169 | 1.0225 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 2 | C14 | 72 | hr | 1401 | 4302 | 4213 | 1.0211 | 1.0264 |
| SK-BR-3 | Vemurafenib | 3.33 | uM | LJP5 | 3 | C14 | 72 | hr | 1401 | 3303 | 4545 | 0.7266 | 0.6570 |
| SK-BR-3 | Vemurafenib | 10 | uM | LJP5 | 1 | C13 | 72 | hr | 1401 | 3922 | 3978 | 0.9858 | 0.9811 |
| SK-BR-3 | Vemurafenib | 10 | uM | LJP5 | 2 | C13 | 72 | hr | 1401 | 3668 | 4213 | 0.8706 | 0.8328 |
| SK-BR-3 | Vemurafenib | 10 | uM | LJP5 | 3 | C13 | 72 | hr | 1401 | 3192 | 4545 | 0.7022 | 0.6240 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 1 | D18 | 72 | hr | 1401 | 4301 | 3978 | 1.0810 | 1.1063 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 2 | D18 | 72 | hr | 1401 | 3940 | 4213 | 0.9351 | 0.9173 |
| SK-BR-3 | Enzastaurin | 0.04 | uM | LJP5 | 3 | D18 | 72 | hr | 1401 | 4539 | 4545 | 0.9985 | 0.9982 |